Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 677-684

  Wang, Hui ^a   Cao, Chuanping ^b   Li, Beilei ^c   Chen, Shaoliang ^c   Yin, Jun ^a   Shi, Jing ^a   Ye, Dan ^b   Tao, Qun ^b   Hu, Peisheng ^d   Epstein, Alan ^d   Ju, Dianwen ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Shanghai GenePharma Co Ltd   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G1; IODINE 131; MONOCLONAL ANTIBODY; TUMOR NECROSIS THERAPY MONOCLONAL ANTIBODY I 131;

ADULT; AGED; ARTICLE; BIOSENSOR; CANCER PATIENT; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SEROLOGY; SERUM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; SURFACE PLASMON RESONANCE;

EID: 43149096699     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0406-0     Document Type: Article

References (34)

1. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43:267-272
2. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598-609
3. Vose JM (2004) Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9:160-172
4. Mirick GR, Bradt BM, Denardo SJ, Denardo GL (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 48:251-257
5. Reff ME, Heard C (2001) A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40:25-35
6. Epstein AL, Chen FM, Taylor CR (1988) A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48:5842-5848
7. 131I-labeled TNT-1 monoclonal antibody. Cancer Res 49:4578-4585
8. Chen FM, Epstein AL., Li Z, Taylor CR (1990) A comparative autoradiographic study demonstrating differential intra-tumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. J Nucl Med 31:1059-1066
9. Epstein AL, Khawli LA, Chen F-M, Hu P, Glasky MS, Taylor CR (1995) Tumor necrosis imaging and treatment of solid tumors. In: Torchillin VP (ed) Handbook of targeted delivery of imaging agents. CRC, Boca Raton, pp 259-288
10. Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL (1998) chTNT-3/B, a new chemically modified chimeric monoclonal antibody directed against DNA for the tumor necrosis treatment of solid tumors. Cancer Biother Radiopharm 13:255-268
11. 2 monoclonal antibody. Antibody Immunoconjugates Radiopharm 4:151-161
12. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW (2005) Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 23:1538-1547
13. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243-1252
14. Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ (2006) Phase I study of 131I-chimeric (ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 21:243-256
15. 131I-chTNT-3 radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 21:5-14
16. Chen FM, Wisner JR Jr, Omachi H, Renner IG, Taylor CR, Epstein AL (1990) Localization of monoclonal antibody TNT-1 in experimental kidney infarction of the mouse. FASEB J 4:3033-3039
17. Anderson PM, Wiseman GA, Lewis BD, Charboneau JW, Dunn WL, Carpenter S, Chew T (2003) A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131I-chTNT-1/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Therapy 1:297-306
18. Granzow R (1994) Biomolecular interaction anlysis. Methods 6:93-205
19. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129
20. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713
21. Milenic DE (2002) Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 8:1749-1764
22. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M (2003) Anticancer antibodies. Am J Clin Pathol 119:472-485
23. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55:1451-1418
24. Pimm MV (1994) Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution. Life Sci 55:PL45-49
25. HAMA Survey Group (1993) Survey of methods for measuring human anti-mouse antibodies. Clin Chim Acta 215:153-163
26. Khazaeli MB, Conry M, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15:42-52
27. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744
28. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671
29. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
30. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
31. DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ (2003) Characterization of human IgG anti-mouse antibody (HAMA) in patients with B-cell malignancies. Clin Cancer Res 9:4013s-4021s
32. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61:6851-6859
33. Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE (2003) Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9:1338-1346
34. Kure M, Katsura Y, Kosano H, Noritake M, Watanabe T, Iwaki Y, Nishigori H, Matsuoka T (2005) A trial to assess the amount of insulin antibodies in diabetic patients by surface plasmon resonance. Intern Med 44:100-106